Stockreport

Neurocrine's Phase II schizophrenia trial fails to meet primary endpoint [Yahoo! Finance]

Neurocrine Biosciences, Inc.  (NBIX) 
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: neurocrine.com/about-us/webcasts-presentations
PDF The randomised, parallel-group, double-blind, placebo-controlled trial enrolled adults with cognitive impairment associated with schizophrenia (CIAS). It assessed the [Read more]